Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease

Neurological Research

Volumn 27, Issue 8, 2005, Pages 869-881

  Watson, Desiree ^a   Castaño, Eduardo ^b   Kokjohn, Tyler A ^c   Kuo, Yu Min ^d   Lyubchenko, Yuri ^e   Pinsky, David ^f   Connolly Jr , E Sander ^g   Esh, Chera ^h   Luehrs, Dean C ^h   Blaine Stine, W ⁱ   Rowse, Linda M ^a   Emmerling, Mark R ^a   Roher, Alex E ^h  

^a PFIZER INC   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c MIDWESTERN UNIVERSITY   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h SUN HEALTH RESEARCH INSTITUTE   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

amyloid; Alzheimer's disease; Atomic force microscopy; ELISA; Neurotoxicity; Oligomer

Indexed keywords

AMYLOID BETA PROTEIN; ION CHANNEL;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GRAY MATTER; NEUROTOXICITY; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; SENILE PLAQUE; SMOOTH MUSCLE FIBER; WHITE MATTER;

3-HYDROXYACYL COA DEHYDROGENASES; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; BIOPOLYMERS; BODY FLUIDS; BRAIN CHEMISTRY; HUMANS; HYDROPHOBICITY; MICE; MICE, TRANSGENIC; MICROGLIA; MICROSCOPY, ATOMIC FORCE; MITOCHONDRIA; MOLECULAR WEIGHT; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RATS; SENILE PLAQUES; SOLUBILITY; VACCINATION;

EID: 29044443820     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X49436     Document Type: Article

References (143)

1. Roher AE, Chaney MO, Kuo YM, et al. Morphology and toxicity of Aβ (1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271: 20631-20635
2. Walsh DM, Lomakin A, Benedek GB, et al. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997; 272: 22364-22372
3. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, et al. Soluble amyloid Aβ(1-40) exists as a stable dimer at low concentrations. J Biol Chem 1997; 272: 21037-21044
4. Chaney MO, Webster SD, Kuo YM, et al. Molecular modeling of the Aβ-42 peptide from Alzheimer's disease. Protein Eng 1998; 11: 761-767
5. Permanne B, Perez C, Soto C, et al. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 1997; 240: 715-720
6. Bitan G, Lomakin A, Teplow DB. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 2001; 276: 35176-35184
7. Soto C, Castano EM. The conformation of Alzheimer's β peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 1996; 314: 701-707
8. Roher AE, Palmer KC, Yurewicz EC, et al. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 1993; 61: 1916-1926
9. Roher AE, Palmer KC, Chan V, et al. Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: Differentiation from amyloid plaque core protein. J Cell Biol 1988; 107: 2703-2716
10. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Sci 2002; 297: 353-356
11. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766
12. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517
13. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32: 177-180
14. Narita M, Holtzman DM, Schwartz AL, et al. α2-Macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 1997; 69: 1904-1911
15. Qiu Z, Strickland DK, Hyman BT, et al. α2-Macroglobulin enhances the clearance of endogenous soluble β-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999; 73: 1393-1398
16. Zerbinatti CV, Wozniak DF, Cirrito J, et al. Increased soluble amyloid-β peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Nat Acad Sci USA 2004; 101: 1075-1080
17. Marr RA, Guan H, Rockenstein E, et al. Neprilysin regulates amyloid β peptide levels. J Mol Neurosci 2004; 22: 5-11
18. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003; 350: 113-116
19. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Nat Acad Sci USA 2003; 100: 4162-4167
20. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J Neurosci 2003; 23: 8867-8871
21. Roher AE, Kasunic TC, Woods AS, et al. Proteolysis of Aβ peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994; 205: 1755-1756
22. Mentlein R, Ludwig R, Martensen I. Protolytic degradation of Alzheimer's disease amyloid β-peptide by a metalloproteinase from microglia cells. J Neurochem 1998; 70: 721-726
23. Kuo YM, Webster S, Emmerling MR, et al. Irreversible dimerization/ tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease. Biochim Biophys Acta 1998; 1406: 291-298
24. Roher AE, Lowenson JD, Clarke S, et al. et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993; 268: 3072-3083
25. Kubo T, Kumagae Y, Miller CA, et al. β-Amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. J Exp Neuropath Exp Neurol 2003; 62: 248-259
26. Kuo YM, Emmerling MR, Woods AS, et al. Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptides from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 1997; 237: 188-191
27. Galeazzi L, Ronchi P, Franceschi C, et al. In vitro peroxidase oxidation induces stable dinners of β-amyloid (1-42) through dityrosine bridge formation. Amyloid 1999; 6: 7-13
28. Yoburn JC, Tian W, Brower JO, et al. Dityrosine cross-linked Aβ peptides: fibrillar β-structure in Aβ(1-40) is conducive to formation of dityrosine cross-links but a dityrosine cross-link in Aβ (8-14) does not induce β-structure. Chem Res Toxicol 2003; 16: 531-535
29. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci 2001; 17: 137-145
30. Knauer MF, Soreghan B, Burdick D, et al. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/β protein. Proc Nat Acad Sci USA 1992; 89: 7437-7441
31. Yanagisawa K, McLaurin J, Michikawa M, et al. Amyloid β-protein (Aβ) associated with lipid molecules: immunoreactivity distinct from that of soluble Aβ. FEBS Lett 1997; 420: 43-46
32. Kawarabayashi T, Shoji M, Younkin LH, et al. Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipo-protein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004; 24: 3801-3809
33. Funato H, Yoshimura M, Kusui K, et al. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998; 152: 1633-1640
34. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary. Neurobiol Aging 1997; 18: S91-S94
35. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18: S1-2
36. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berlin) 1991; 82: 239-259
37. Walsh DM, Klyubin I, Fadeeva JV, et al. Amyloid-β oligomers: their production, toxicity and theraputic inhibition. Biochem Soc Trans 2002; 30: 552-557
38. Weller RO, Yow HY, Preston SD, et al. Cerebrovascular disease is a major factor in the failure of elimination of Aβ from the aging human brain: implications for therapy of Alzheimer's disease. Ann NY Acad Sci 2002; 977: 162-168
39. Roher AE, Esh C, Kokjohn TA, et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-2062
40. Roher AE, Kuo YM, Esh C, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 2003; 9: 112-122
41. Roher AE, Lowenstein JD, Clarke S, et al. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer's disease. Proc Nat Acad Sci USA 1993; 90: 10836-10840
42. Ghetti B, Dlouhy SR, Giaccone G, et al. Gerstmann-Straussler-Scheinker disease and the Indiana kindred. Brain Pathol 1995; 5: 61-75
43. Yamazaki M, Oyanagi K, Mori O, et al. Variant Gerstmann-Straussler syndrome with the P105L prion gene mutation: An unusual case with nigral degeneration and widespread neurofibrillary tangles. Acta Neuropathol (Berlin) 1999; 98: 506-511
44. Mohr M, Tranchant C, Steinmetz G, et al. Gerstmann-Straussler-Scheinker disease and the French-Alsatian A117V variant. Clin Exp Pathol 1999; 47: 161 -175
45. De Michele G, Pocchiari M, Petraroli R, et al. Variable phenotype in a P102L Gerstmann-Straussler-Scheinker Italian family. Can J Neurol Sci 2003; 30: 233-236
46. Pearlman RL, Towfighi J, Pezeshkpour GH, et al. Clinical significance of types of cerebellar amyloid plaques in human spongiform encephalopathies. Neurology 1988; 38: 1249-1254
47. Ghorayeb I, Series C, Parchi P, et al. Creutzfeldt-Jakob disease with long duration and panencephalopathic lesions: molecular analysis of one case. Neurology 1998; 51: 271-274
48. Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology 1997; 49: 126-133
49. Tanaka S, Ota M, Ohama E. A case of sporadic Creutzfeldt-Jakob disease with both plaque and synaptic-type deposition of prion protein. Neuropathology 2000; 20: 49-55
50. Liberski PP, Ironside J, McCardle L, et al. Ultrastructural analysis of the florid plaque in variant Creutzfeldt-Jakob disease. Folia Neuropathol 2000; 38: 167-170
51. Armstrong RA, Lantos PL, Ironside JW, et al. Differences in the density and spatial distribution of florid and diffuse plaques in variant Creutzfeldt-Jakob disease (vCJD). Clin Neuropathol 2003; 22: 209-214
52. Austen B, el-Agnaf O, Nagala S, et al. Properties of neurotoxic peptides related to the BRI gene. Biochem Soc Trans 2002; 30: 557-559
53. Gibson G, Gunasekera N, Lee M, et al. Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. J Neurochem 2004; 88: 281-290
54. Holton JL, Ghiso J, Lashley T, et al. Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol 2001; 158: 515-526
55. Holton JL, Lashley T, Ghiso J, et al. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-β. J Neuropathol Exp Neurol 2002; 61: 254-2670
56. Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 1998; 57: 885-894
57. Weller RO, Massey A, Kuo YM, et al. Cerebral amyloid angiopathy: accumulation of Aβ in interstitial fluid drainage pathways in Alzheimer's disease. Ann NY Acad Sci 2000; 903: 110-117
58. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: Amyloid-β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998; 153: 725-733
59. Weller RO, Kida S, Zhang ET. Pathways of fluid drainage from the brain-morphological aspects and immunological significance in rat and man. Brain Pathol 1992; 2: 277-284
60. Yamada S, DePasquale M, Patlak CS, et al. Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 1991; 261: H1197-1204
61. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 1992; 2: 269-276
62. Van Dorpe J, Smeijers L, Dewachter I, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol 2000; 157: 1283-1298
63. Tabaton M, Nunzi MG, Xue R, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994; 200: 1598-1603
64. Harigaya Y, Shoji M, Kawarabayashi T, et al. Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 1995; 211: 1015-1022
65. Tamoaka A, Kondo T, Odaka A, et al. Biochemical evidence for the long-tail form (Aβ 1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994; 205: 834-842
66. Podlisny MB, Ostaszewski BL, Squazzo EL, et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995; 270: 9564-9570
67. Podlisny MB, Walsh DM, Amarante P, et al. Oligomerization of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochem 1998; 37: 3602-3611
68. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2: 93-95
69. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Aβ (N-40, N-42) oligimers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-4081
70. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Nat Acad Sci USA 1998; 95: 6448-6453
71. Roher AE, Weiss N, Kokjohn TA, et al. Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochem 2002; 41: 11080-11090
72. Pitschke M, Prior R, Haupt M, et al. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998; 4: 832-834
73. Walsh DM, Tseng BP, Rydel RE, et al. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochem 2000; 39: 10831-10839
74. Lee JT, Xu J, Lee JM, et al. Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164: 123-131
75. Lansbury PT Jr, Costa PR, Griffiths JM, et al. Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol 1995; 2: 990-998
76. Roher AE, Baudry J, Chaney MO, et al. Oligomerization and fibril assembly of the amyloid-β protein. Biochim Biophys Acta 2000; 1502: 31-43
77. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of β-amyloid play critical roles in aggregation. J Neurosci Res 2004; 75: 162-171
78. Gorman PM, Yip CM, Fraser PE, et al. Alternate aggregation pathways of the Alzheimer β-amyloid peptide: Aβ association kinetics at endosomal pH. J Mol Biol 2003; 325: 743-757
79. Huang THJ, Yang DS, Plaskos NP, et al. Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide. J Mol Biol 2000; 297: 73-87
80. Hoshi M, Sato M, Matsumoto S, et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase 1/glycogen synthase kinase-3β. Proc Nat Acad Sci USA 2003; 100: 6370-6375
81. 1-42 into globular neurotoxins. Biochemistry 2003; 42: 12749-12760
82. Pillot T, Goethals M, Vanloo B, et al. Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J Biol Chem 1996; 271: 28757-28765
83. Arispe N, Pollard HB, Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein in bilayer membranes. Proc Natl Acad Sci USA 1993; 90: 10573-10577
84. Lin H, Bhatia R, Lal R. Amyloid β forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB J 2001; 15: 2433-2444
85. Durell SR, Guy HR, Arispe N, et al. Theoretical models of the ion channel structure of amyloid β-protein. Biophys J 1994; 67: 2137-2145
86. Kagan BL, Hirakura Y, Azimov R, et al. The channel hypothesis of Alzheimer's disease: Current status. Peptides 2002; 23: 1311-1315
87. Pollard HB, Rojas E, Arispe N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid β protein (AβP) in phospholipid bilayer mechanism. Ann NY Acad Sci 1993; 695: 165-168
88. Bhatia R, Lin H, Lal R. Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. FASEB J 2000; 14: 1233-1243
89. Zhu YJ, Lin H, Lal R. Fresh and nonfibrillar amyloid β protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: Evidence for AβP-channel-mediated cellular toxicity. FASEB J 2000; 14: 1244-1254
90. Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's β-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res Bull 2000; 53: 389-397
91. Kourie JI, Henry CL, Farrely P. Diversity of amyloid β protein fragment [1-40]-formed channels. Cell Mol Neurobiol 2001; 21: 255-284
92. Kourie JI, Culverson AL, Farrelly PV, et al. Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: Implications for therapeutic strategies against amyloidosis. Cell Biochem Biophys 2002; 36: 191-207
93. Lashuel HA, Hartley D, Petre BM, et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 2002; 418: 291-291
94. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866
95. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid-β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-862
96. Giulian D, Haverkamp L, Yu J, et al. Specific domains of β-amyloid from Alzheimer's plaque elicit neuron killing in human microglia. J Neurosci 1996; 16: 6021-6037
97. Giulian D, Haverkamp LJ, Yu J, et al. The HHQK domain of β-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 1998; 273: 29719-29726
98. Hu J, Akama KT, Krafft CA, et al. Amyloid-β peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998; 785: 195-206
99. Haas J, Storch-Hagenlocher B, Biessmann A, et al. Inducible nitric oxide synthase and argininosuccinate synthetase: Coinduction in brain tissue of patients with Alzheimer's dementia and following stimulation with β-amyloid 1-42 in vitro. Neurosci Lett 2002; 322: 121-125
100. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96: 3228-3233
101. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-4058
102. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539
103. Puolivali J, Wang J, Heikkinen T, et al. Hippocampal Aβ 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 2002; 9; 339-347
104. Koistinaho M, Ort M, Cimadevilla JM, et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 2001; 98: 14675-14680
105. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22: 6331-6335
106. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22: 1858-1867
107. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-457
108. Thomas T, Thomas G, McLendon C, et al. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-171
109. Crawford F, Suo Z, Fang C, et al. The vasoactivity of Aβ peptides. Ann NY Acad Sci 1997; 826: 35-46
110. Crawford F, Suo Z, Fang C, et al. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol 1998; 150: 159-168
111. Price JM, Chi X, Hellermann G, et al. Physiological levels of β-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurological Res 2001; 23: 506-512
112. Paris D, Town T, Mori T, et al. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 2000; 21: 183-197
113. Paris D, Town T, Parker T, et al. Aβ vasoactivity: An inflammatory reaction. Ann NY Acad Sci 2000; 903: 97-109
114. Paris D, Town T, Parker TA, et al. Inhibition of Alzheimer's β-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP dependent mechanism. Exp Neurol 1999; 157: 211-221
115. Paris D, Townsend KP, Humphrey J, et al. Statins inhibit Aβ-neurotoxicity in vitro and Aβ-induced vasoconstriction and imflammation in rat aortae. Atherosclerosis 2002; 161: 293-299
116. Niwa K, Porter VA, Kazama K, et al. Aβ peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281: H2417-2424
117. Niwa K, Kazama K, Younkin SG, et al. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9: 61-68
118. Niwa K, Younkin L, Ebeling C, et al. Aβ 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA 2000; 97: 9735-9740
119. Zhang F, Eckman C, Younkin S, et al. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci 1997; 17: 7655-7661
120. Niwa K, Kazama K, Younkin L, et al. Cerebrovascular auto-regulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283: H315-323
121. Iadecola C. Cerebrovascular effects of amyloid-β peptides: mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 2003; 23: 681-689
122. Paris D, Townsend K, Quadros A, et al. Inhibition of angiogenesis by Aβ peptides. Angiogenesis 2004; 7: 75-85
123. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-452
124. Yan SD, Shi Y, Zhu A, et al. Role of ERAB/L-3-hydroxyacylcoenzyme A dehydrogenase type II activity in Aβ-induced cytotoxicity. J Biol Chem 1999; 274: 2145-2156
125. Elkabetz Y, Shapira I, Rabinovich E, et al. Distinct steps in dislocation of luminal endoplasmic reticulum-associated degredation substrates: Roles of endoplasmic reticulum-bound p97/Cdc48p and proteasome. J Biol Chem 2004; 279: 3980-3989
126. Schmitz A, Schneider A., Kummer MP, et al. Endoplasmic reticulum-localized amyloid β-peptide is degraded in the cytosol by two distinct degradation pathways. Traffic 2004; 5: 89-101
127. Yan SD, Fu J, Soto C, et al. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997; 389: 689-695
128. Matouschek A, Pfanner N, Voss W. Protein unfolding by mitochondria. The Hsp70 import motor. EMBO Rep 2000; 1: 404-410
129. Verdier Y, Zarandi M, Penke B. Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Peptide Sci 2004; 10: 229-248
130. Ofman R, Ruiter JP, Feenstra M, et al. 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am J Hum Genet 2003; 72: 1300-1307
131. Plant LD, Boyle JP, Smith IF, et al. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23: 5531-5535
132. Lopez-Toledano M, Shelanski ML. Neurogenic effect of β-amyloid peptide in the development of neural stem cells. J Neurosci 2004; 24: 5439-5444
133. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 2003; 23: 8844-8853
134. Hartley DM, Walsh DM, Ye CP, et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-8884
135. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489
136. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985
137. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102
138. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav 2001; 73: 873-886
139. Younkin SG. Amyloid β vaccination: reduced plaques and improved cognition. Nat Med 2001; 7: 18-19
140. Schenk D, Barbour R, Dunn W, et al. Immmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177
141. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer's disease following immunization with amyloid-β-peptide: A case report. Nat Med 2003; 9: 448-452
142. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-β immunizaton in Alzheimer's disease. Brain Pathol 2004; 14: 11-20
143. Hock C, Konietzko U, Streffer JR, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554